Research Study: OPUS Registry
Condition:
pulmonary arterial hypertension
Study Sponsor: Actelion
Study Investigator: Barry Cabuay, MD
Study Contact: Sarah Dennis, RN
sarah.dennis@allina.com
612-863-6257
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
Eligibility Criteria:

  • Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days prior to enrollment visit.
  • Signed ICF

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!